These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 34625296)
1. Development of an extension of the OMERACT Summary of Measurement Properties table to capture equity considerations: SOMP-Equity. Petkovic J; Umaefulam V; Wattiaux A; Bartels C; Barnabe C; Greer-Smith R; Hofstetter C; Maxwell L; Shea B; Barton J; Lee AYS; Humphreys J; Beaton D; Tugwell P Semin Arthritis Rheum; 2021 Dec; 51(6):1300-1310. PubMed ID: 34625296 [TBL] [Abstract][Full Text] [Related]
2. Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group. Petkovic J; Barton JL; Flurey C; Goel N; Bartels CM; Barnabe C; de Wit MPT; Lyddiatt A; Lacaille D; Welch V; Boonen A; Shea B; Christensen R; Maxwell LJ; Campbell W; Jull J; Toupin-April K; Singh JA; Goldsmith CH; Sreih AG; Pohl C; Hofstetter C; Beaton DE; Buchbinder R; Guillemin F; Tugwell PS J Rheumatol; 2017 Nov; 44(11):1727-1733. PubMed ID: 28202740 [TBL] [Abstract][Full Text] [Related]
3. OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. Leung YY; Orbai AM; Hojgaard P; Holland R; Mathew AJ; Goel N; Chau J; Tillett W; Lindsay C; Ogdie A; Coates LC; Gladman DD; Christensen R; Mease P; Strand V Semin Arthritis Rheum; 2021 Oct; 51(5):1117-1124. PubMed ID: 34392975 [TBL] [Abstract][Full Text] [Related]
4. Validation studies of rheumatoid arthritis patient-reported outcome measures in populations at risk for inequity: A systematic review and analysis using the OMERACT summary of measurement properties equity table. Barnabe C; Wattiaux A; Petkovic J; Beaton D; Shea B; Greer-Smith R; Humphreys J; Bartels C; Tugwell P; Umaefulam V Semin Arthritis Rheum; 2022 Aug; 55():152029. PubMed ID: 35640489 [TBL] [Abstract][Full Text] [Related]
5. Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. Beaton DE; Maxwell LJ; Shea BJ; Wells GA; Boers M; Grosskleg S; Bingham CO; Conaghan PG; D'Agostino MA; de Wit MP; Gossec L; March LM; Simon LS; Singh JA; Strand V; Tugwell P J Rheumatol; 2019 Aug; 46(8):1028-1035. PubMed ID: 30709952 [TBL] [Abstract][Full Text] [Related]
6. The evolution of instrument selection for inclusion in core outcome sets at OMERACT: Filter 2.2. Maxwell LJ; Beaton DE; Boers M; D'Agostino MA; Conaghan PG; Grosskleg S; Shea BJ; Bingham Iii CO; Boonen A; Christensen R; Choy E; Doria AS; Hill CL; Hofstetter C; Kroon FP; Leung YY; Mackie S; Meara A; Touma Z; Tugwell P; Wells GA Semin Arthritis Rheum; 2021 Dec; 51(6):1320-1330. PubMed ID: 34544617 [TBL] [Abstract][Full Text] [Related]
7. A review of health equity considerations in Cochrane reviews of lifestyle interventions for cardiovascular health in adults. Nyanchoka M; Alade OT; Petkovic J; Duque T; Wieland LS J Clin Epidemiol; 2024 Dec; 176():111546. PubMed ID: 39343415 [TBL] [Abstract][Full Text] [Related]
8. Core outcome measurement instrument selection for physical function in hand osteoarthritis using the OMERACT Filter 2.1 process. Kroon FPB; van der Heijde D; Maxwell LJ; Beaton DE; Abishek A; Berenbaum F; Blanco FJ; Conaghan PG; Dziedzic K; Hill CL; Haugen IK; Ishimori M; Ritschl V; Stamm TA; Wittoek R; Kloppenburg M Semin Arthritis Rheum; 2021 Dec; 51(6):1311-1319. PubMed ID: 34538514 [TBL] [Abstract][Full Text] [Related]
9. Reporting of health equity considerations in cluster and individually randomized trials. Petkovic J; Jull J; Yoganathan M; Dewidar O; Baird S; Grimshaw JM; Johansson KA; Kristjansson E; McGowan J; Moher D; Petticrew M; Robberstad B; Shea B; Tugwell P; Volmink J; Wells GA; Whitehead M; Cuervo LG; White H; Taljaard M; Welch V Trials; 2020 Apr; 21(1):308. PubMed ID: 32245522 [TBL] [Abstract][Full Text] [Related]
10. How Is Health Equity Assessed in Cochrane Musculoskeletal Reviews? Janusz N; Dewidar O; Dowling S; Wang H; Buchbinder R; Conde M; Ghogomu ET; Maxwell L; Tugwell P; Howe T; Welch V J Rheumatol; 2022 Dec; 49(12):1379-1384. PubMed ID: 35970529 [TBL] [Abstract][Full Text] [Related]
11. Assessment of health equity consideration in masking/PPE policies to contain COVID-19 using PROGRESS-plus framework: a systematic review. Chhibber A; Kharat A; Kneale D; Welch V; Bangpan M; Chaiyakunapruk N BMC Public Health; 2021 Sep; 21(1):1682. PubMed ID: 34525995 [TBL] [Abstract][Full Text] [Related]
12. Reporting of health equity considerations in vaccine trials for COVID-19: a methodological review. Kou R; Sadafi SL; Principato R; Anderson LN; Brignardello-Petersen R; Mbuagbaw L J Clin Epidemiol; 2024 May; 169():111315. PubMed ID: 38447854 [TBL] [Abstract][Full Text] [Related]
13. Using PROGRESS-plus to identify current approaches to the collection and reporting of equity-relevant data: a scoping review. Karran EL; Cashin AG; Barker T; Boyd MA; Chiarotto A; Dewidar O; Mohabir V; Petkovic J; Sharma S; Tejani S; Tugwell P; Moseley GL J Clin Epidemiol; 2023 Nov; 163():70-78. PubMed ID: 37802205 [TBL] [Abstract][Full Text] [Related]
14. PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. Orbai AM; Holland R; Leung YY; Tillett W; Goel N; Christensen R; McHugh N; Gossec L; de Wit M; Højgaard P; Coates LC; Mease PJ; Birt J; Fallon L; FitzGerald O; Ogdie A; Shea B; Strand V; Duffin KC; Tugwell P; Beaton D; Gladman DD J Rheumatol; 2019 Aug; 46(8):990-995. PubMed ID: 30554154 [TBL] [Abstract][Full Text] [Related]
15. How to choose core outcome measurement sets for clinical trials: OMERACT 11 approves filter 2.0. Boers M; Kirwan JR; Gossec L; Conaghan PG; D'Agostino MA; Bingham CO; Brooks PM; Landewé R; March L; Simon L; Singh JA; Strand V; Wells GA; Tugwell P J Rheumatol; 2014 May; 41(5):1025-30. PubMed ID: 24584913 [TBL] [Abstract][Full Text] [Related]
16. Do quality improvement initiatives for diabetes care address social inequities? Secondary analysis of a systematic review. Lu JB; Danko KJ; Elfassy MD; Welch V; Grimshaw JM; Ivers NM BMJ Open; 2018 Feb; 8(2):e018826. PubMed ID: 29444781 [TBL] [Abstract][Full Text] [Related]
17. Smart City and High-Tech Urban Interventions Targeting Human Health: An Equity-Focused Systematic Review. Buttazzoni A; Veenhof M; Minaker L Int J Environ Res Public Health; 2020 Mar; 17(7):. PubMed ID: 32235594 [TBL] [Abstract][Full Text] [Related]
18. Considerations and guidance in designing equity-relevant clinical trials. Mbuagbaw L; Aves T; Shea B; Jull J; Welch V; Taljaard M; Yoganathan M; Greer-Smith R; Wells G; Tugwell P Int J Equity Health; 2017 Jun; 16(1):93. PubMed ID: 28583125 [TBL] [Abstract][Full Text] [Related]
19. Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. Holland R; Tillett W; Ogdie A; Leung YY; Gladman DD; Callis Duffin K; Coates LC; Mease PJ; Eder L; Strand V; Elmamoun M; Højgaard P; Chau J; de Wit M; Goel N; Lindsay CA; FitzGerald O; Shea B; Beaton D; Orbai AM J Rheumatol Suppl; 2018 Jun; 94():17-25. PubMed ID: 29858348 [TBL] [Abstract][Full Text] [Related]
20. Reporting of determinants of health inequities and participant characteristics in randomized controlled trials of systemic lupus erythematosus in Canada: A scoping review. Thomas M; Verma V; Gheshlaghi N; Esdaile J; Avina-Zubieta A; Barnabe C; Harrison M; De Vera MA Lupus; 2024 Apr; 33(5):462-469. PubMed ID: 38339797 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]